Two Sigma Advisers LP Buys 308,000 Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX)

Two Sigma Advisers LP boosted its position in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) by 69.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 754,000 shares of the company's stock after purchasing an additional 308,000 shares during the period. Two Sigma Advisers LP owned 0.20% of GoodRx worth $3,506,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. grew its holdings in shares of GoodRx by 358.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 24,293 shares of the company's stock valued at $169,000 after acquiring an additional 18,997 shares in the last quarter. Gagnon Securities LLC boosted its holdings in GoodRx by 9.9% in the fourth quarter. Gagnon Securities LLC now owns 69,867 shares of the company's stock worth $325,000 after purchasing an additional 6,266 shares in the last quarter. IMC Chicago LLC bought a new stake in GoodRx in the fourth quarter worth $304,000. Olympiad Research LP bought a new stake in GoodRx in the fourth quarter worth $147,000. Finally, Bank of New York Mellon Corp boosted its holdings in GoodRx by 10.1% in the fourth quarter. Bank of New York Mellon Corp now owns 192,612 shares of the company's stock worth $896,000 after purchasing an additional 17,633 shares in the last quarter. 63.77% of the stock is currently owned by hedge funds and other institutional investors.

GoodRx Stock Performance

Shares of GDRX traded up $0.10 during trading hours on Friday, reaching $3.91. 1,158,653 shares of the company traded hands, compared to its average volume of 1,379,478. The company has a debt-to-equity ratio of 0.70, a quick ratio of 5.48 and a current ratio of 5.48. The stock's fifty day moving average is $4.30 and its 200 day moving average is $4.55. GoodRx Holdings, Inc. has a 1-year low of $3.68 and a 1-year high of $9.26. The stock has a market cap of $1.40 billion, a P/E ratio of -130.33, a price-to-earnings-growth ratio of 2.46 and a beta of 1.24.

GoodRx (NASDAQ:GDRX - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported $0.09 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.05. The business had revenue of $202.97 million for the quarter, compared to analyst estimates of $202.25 million. GoodRx had a negative net margin of 2.05% and a positive return on equity of 5.35%. The firm's revenue was up 2.6% on a year-over-year basis. During the same period in the previous year, the business earned $0.08 EPS. Equities research analysts anticipate that GoodRx Holdings, Inc. will post 0.13 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on GDRX shares. The Goldman Sachs Group decreased their price objective on shares of GoodRx from $6.00 to $5.00 and set a "neutral" rating for the company in a report on Friday, May 9th. Wells Fargo & Company decreased their price objective on shares of GoodRx from $8.00 to $7.00 and set an "overweight" rating for the company in a report on Tuesday, April 29th. Truist Financial decreased their price objective on shares of GoodRx from $6.50 to $5.50 and set a "hold" rating for the company in a report on Thursday, April 10th. Finally, UBS Group decreased their price objective on shares of GoodRx from $6.00 to $5.25 and set a "neutral" rating for the company in a report on Tuesday, May 13th. Five analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $6.55.

GoodRx Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.